Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 15.07.21 with a price of €144.00. The price for Alnylam Pharmace. massively increased, which is bad news for the SELL prediction by Biotechhunter. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | -3.946% | -3.946% | -25.843% | 17.551% |
iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren